Trial · NCT05787860

Ruxolitinib in Seborrheic Dermatitis

NCT05787860, Phase 2, Completed, Icahn School of Medicine at Mount Sinai; results first posted 2025-05-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Ruxolitinib in Seborrheic Dermatitis. Trials, record NCT05787860. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05787860

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Ruxolitinib in Seborrheic Dermatitis
NCT number: NCT05787860
Status: Completed
Phases: Phase 2
Enrollment: 45 participants, actual
Lead sponsor: Icahn School of Medicine at Mount Sinai
Conditions: Seborrheic Dermatitis
Interventions: Ruxolitinib 1.5% Cream
First posted: 2023-03-28
Last updated: 2025-05-06
Results first posted: 2025-05-06

Source ClinicalTrials.gov

Registered outcomes9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Investigator Global Assessment of 0 or 1 at Week 4	At end of Treatment, Week 4	Number of Participants with Investigator Global Assessment of 0 or 1 at Week 4 IGA Scale from 0-4 Clear 0 No signs of SD Almost Clear 1 Just perceptible erythema and just perceptible scaling Mild 2 Mild erythema and mild scaling Moderate 3 Moderate erythema and moderate scaling Severe 4 Severe erythema and severe scaling
Secondary	Change in Investigator Global Assessment From Baseline to Week 4	Baseline and Week 4	IGA Scale from 0-4 Clear 0 No signs of SD Almost Clear 1 Just perceptible erythema and just perceptible scaling Mild 2 Mild erythema and mild scaling Moderate 3 Moderate erythema and moderate scaling Severe 4 Severe erythema and severe scaling
Secondary	Mean Change in Seborrheic Dermatitis Severity Score	Baseline, Week 4, Week 6	Mean Change in seborrheic dermatitis severity score from baseline and week 4, baseline a d week 6 and week 4 and week 6 SD Severity Score (the sum of the three clinical features for a total score ranging from 0-12), where higher scores indicate more severe outcomes. Scale 0-4 Erythema 0-4 Pruritus 0-4 (0 = absence, 1 = mild, 2 = moderate, 3 = significant, 4 = severe)
Secondary	Mean Change in Seborrheic Dermatitis Severity Score for Scale	Baseline, Week 4, and Week 6	Mean Change in seborrheic dermatitis severity score for Scale from baseline and week 4, baseline and week 6, week 4 and week 6 Scale 0-4, where higher scores indicate more severe outcomes. (0 = absence, 1 = mild, 2 = moderate, 3 = significant, 4 = severe)
Secondary	Change in Seborrheic Dermatitis Severity Score for Erythema	Baseline, Week 4, and Week 6	Change in seborrheic dermatitis severity score for Erythema from baseline and week 4, baseline and week 6, week 4 and week 6 Erythema 0-4, where higher scores indicate more severe outcomes. (0 = absence, 1 = mild, 2 = moderate, 3 = significant, 4 = severe)
Secondary	Change in Seborrheic Dermatitis Severity Score for Pruritus	Baseline Week 4, and Week 6	Change in seborrheic dermatitis severity score for Pruritus from baseline and week 4, baseline and week 6, week 4 and week 6 Pruritus 0-4, where higher scores indicate more severe outcomes. (0 = absence, 1 = mild, 2 = moderate, 3 = significant, 4 = severe)
Secondary	Frequency of Adverse Events	6 weeks
Secondary	Duration of Adverse Events	6 weeks
Secondary	Severity of Adverse Events	6 weeks	Severity will be measured as a category (mild, moderate, or severe).

Source ClinicalTrials.gov

Outcomes9

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Investigator Global Assessment of 0 or 1 at Week 4	At end of Treatment, Week 4	Data collected only for participants with SD	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Change in Investigator Global Assessment From Baseline to Week 4	Baseline and Week 4	Data collected only for participants with SD	score on a scale	MEAN
SECONDARY	Mean Change in Seborrheic Dermatitis Severity Score	Baseline, Week 4, Week 6	Data collected only for participants with SD	mean change in score on a scale	MEAN
SECONDARY	Mean Change in Seborrheic Dermatitis Severity Score for Scale	Baseline, Week 4, and Week 6	Data collected only for participants with SD	mean change in score on a scale	MEAN
SECONDARY	Change in Seborrheic Dermatitis Severity Score for Erythema	Baseline, Week 4, and Week 6	Data collected only for participants with SD	mean change in score on a scale	MEAN
SECONDARY	Change in Seborrheic Dermatitis Severity Score for Pruritus	Baseline Week 4, and Week 6	Data collected only for participants with SD	mean change in score on a scale	MEAN
SECONDARY	Frequency of Adverse Events	6 weeks		events	NUMBER
SECONDARY	Duration of Adverse Events	6 weeks	As there were no adverse events, duration could not be calculated.
SECONDARY	Severity of Adverse Events	6 weeks	As there were no adverse events, severity of adverse events could not be calculated.

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Participants With Investigator Global Assessment of 0 or 1 at Week 4	Ruxolitinib Cream		20		Participants
Change in Investigator Global Assessment From Baseline to Week 4	Ruxolitinib Cream		-2.16	Standard Deviation 0.69	score on a scale
Mean Change in Seborrheic Dermatitis Severity Score	Ruxolitinib Cream	baseline and week 4	-6	Standard Deviation 1.61	mean change in score on a scale
Mean Change in Seborrheic Dermatitis Severity Score	Ruxolitinib Cream	baseline and week 6	-2.8	Standard Deviation 2.96	mean change in score on a scale
Mean Change in Seborrheic Dermatitis Severity Score	Ruxolitinib Cream	week 4 and week 6	3.2	Standard Deviation 2.52	mean change in score on a scale
Mean Change in Seborrheic Dermatitis Severity Score for Scale	Ruxolitinib Cream	baseline and week 4	-1.56	Standard Deviation 0.87	mean change in score on a scale
Mean Change in Seborrheic Dermatitis Severity Score for Scale	Ruxolitinib Cream	baseline and week 6	-0.56	Standard Deviation 1.29	mean change in score on a scale
Mean Change in Seborrheic Dermatitis Severity Score for Scale	Ruxolitinib Cream	week 4 and week 6	3.2	Standard Deviation 2.52	mean change in score on a scale
Change in Seborrheic Dermatitis Severity Score for Erythema	Ruxolitinib Cream	baseline and week 4	-2	Standard Deviation 0.76	mean change in score on a scale
Change in Seborrheic Dermatitis Severity Score for Erythema	Ruxolitinib Cream	baseline and week 6	-1.04	Standard Deviation 1.06	mean change in score on a scale

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Ruxolitinib Cream	25
Overall Study	STARTED	Healthy Control Subjects	20
Overall Study	COMPLETED	Ruxolitinib Cream	25
Overall Study	COMPLETED	Healthy Control Subjects	20
Overall Study	NOT COMPLETED	Ruxolitinib Cream	0
Overall Study	NOT COMPLETED	Healthy Control Subjects	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Ruxolitinib Cream	25
Total, all-cause mortality	Healthy Control Subjects	20
Total, other adverse events	Ruxolitinib Cream	25
Total, other adverse events	Healthy Control Subjects	20
Total, serious adverse events	Ruxolitinib Cream	25
Total, serious adverse events	Healthy Control Subjects	20

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Ruxolitinib Cream vs Healthy Control Subjects: deaths from any cause	Trial comparisons
Ruxolitinib Cream vs Healthy Control Subjects: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05787860

GET https://conductscience.org/api/trials/v1/NCT05787860/registered

API reference For AI assistants